|1.||Clevert, D-A: 6 articles (03/2010 - 01/2008)|
|2.||Strobel, D: 5 articles (12/2012 - 05/2005)|
|3.||Reiser, M: 5 articles (10/2011 - 01/2008)|
|4.||Yang, Wei: 4 articles (01/2016 - 12/2005)|
|5.||Lassau, Nathalie: 4 articles (04/2015 - 05/2006)|
|6.||Lin, Win-Li: 4 articles (08/2012 - 10/2009)|
|7.||Stock, K: 4 articles (01/2010 - 01/2008)|
|8.||Jung, E M: 4 articles (01/2010 - 12/2007)|
|9.||Bokor, D: 4 articles (12/2009 - 08/2000)|
|10.||Luo, Wen: 4 articles (08/2009 - 05/2007)|
12/01/2012 - "In the tumor model, SonoVue was rapidly cleared from the circulation, without any noticeable binding in the tumor, whereas BR55 showed a gradual decline, resulting in a longer wash-out period (mean transit time: P < .01). "
12/01/2009 - "It was the aim of our study to establish the extent to which contrast enhancement with SonoVue(R) in combination with quantitative evaluation of contrast-medium dynamics facilitates the detection of malignant hepatic tumors. "
01/01/2015 - "The in vivo enhancement intensity in the tumor was stronger than that of SonoVue after injection (UCA; 2 min: 162.47 ± 8.94 dB vs. 132.11 ± 5.16 dB, P < 0.01; 5 min: 128.38.47 ± 5.06 dB vs. 68.24 ± 2.07 dB, P < 0.01). "
01/01/2014 - "CE-US measurements were performed by intravenous application of a contrast agent (SonoVue, Bracco, Italy) before surgical tumor resection. "
01/01/2014 - "Combined ultrasound and SonoVue treatment produced greater tumor regression than either treatment alone (p < 0.05). "
|2.||Neoplasm Metastasis (Metastasis)
08/01/2009 - "CEUS combined with SonoVue is useful for detecting SLNs, although it may not be helpful for detecting metastases in SLNs."
08/01/2005 - "Detection of hepatic metastases is substantially improved by low MI real time contrast enhanced ultrasound with SonoVue compared to conventional B-mode sonography."
02/01/2009 - "This study was done to assess the enhancement characteristics of splenic implants and to evaluate whether contrast-enhanced ultrasound (CEUS) after SonoVue injection allows the differential diagnosis with peritoneal metastases. "
08/01/2005 - "The aim of this study was to compare low mechanical index (MI) real time contrast enhanced ultrasound of the liver, using the contrast agent SonoVue, with conventional B-mode sonography for the detection of hepatic metastases. "
01/01/2014 - "Sixteen liver metastasis lesions underwent a rapid wash-out of contrast agent during the portal venous phase followed by a complete wash-out of SonoVue during the sinusoidal phase and were differentiated as "fast-in and fast-out" contrast enhancement patter. "
|3.||Hepatocellular Carcinoma (Hepatoma)
12/20/2005 - "The advent of second generation agent-SonoVue and low mechanical index real-time contrast enhanced ultrasonography (CEUS) imaging have been shown to improve the diagnostic performance of ultrasonography in hepatocellular carcinoma (HCC). "
12/01/2009 - "The aim of the study was to characterize SonoVue enhancement in hepatocellular carcinoma in correlation to both lesion diameter and histological differentiation of the lesion. "
10/18/2005 - "To investigate the diagnostic value of contrast-enhanced ultrasound (CEUS) enhancement patterns of hepatocellular carcinoma (HCC) smaller than 2 cm. From 392 cases with focal liver lesions undergoing CEUS with SonoVue and Contrast Tuned Imaging (CnTI) technique, thirty six cirrhotic patients with thirty eight HCCs with histopathological diagnosis were retrospectively analyzed in this study. "
01/01/2016 - "We aimed to investigate the enhancement patterns of contrast-enhanced ultrasound (CEUS) with SonoVue and determine the utility of this method for differential diagnosis between hepatic inflammatory lesions with arterial phase enhancement and hepatocellular carcinomas (HCC). "
01/01/2010 - "We evaluated 25 patients with proven hepatocellular carcinoma, who underwent dynamic contrast-enhanced ultrasound (CEUS) using a second generation contrast agent (SonoVue, Bracco, Germany). "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/2002 - "We report our clinical experience for diagnosis of coronary artery disease (CAD) and in particular, first experimental and clinical results with SonoVue, a new echo contrast agent."
11/01/2000 - "Two hundred and eighteen patients with suspected coronary artery disease undergoing fundamental echocardiography for the assessment of left ventricle were enrolled in a prospective multicenter, single blind, cross-over study with random sequence allocation of four different doses of SonoVue. "
08/17/2000 - "The possibility of detecting myocardial perfusion defects using SonoVue-enhanced power Doppler and gray-scale harmonic contrast echocardiography associated with continuous and intermittent imaging was assessed in patients with coronary artery disease. "
02/01/2000 - "Fifteen patients with known coronary artery disease and a resting perfusion abnormality on Tc-99m sestamibi single-photon emission computed tomography (SPECT) underwent PDHI at rest during intravenous injections of 2 to 3 mL of Sonovue (Bracco SpA, Milan, Italy), a new second-generation ultrasound contrast agent. "
10/08/2013 - "(A phase III study to compare SonoVue® enhanced myocardial echocardiography [MCE] to single photon emission computerized tomography [ECG-GATED SPECT], at rest and at peak of low-dose Dipyridamole stress test, in the assessment of significant coronary artery disease [CAD] in patients with suspect or known CAD using Coronary Angiography as Gold Standard-SonoVue MCE vs SPECT; EUCTR2007-003492-39-GR)."
|5.||Renal Cell Carcinoma (Grawitz Tumor)
06/01/2011 - "To assess the efficacy of contrast-enhanced ultrasonography (CEUS) with Sonovue in the evaluation of therapeutic response to radiofrequency ablation (RFA) of renal cell carcinoma (RCC). "
01/01/2013 - "The aim of the study was to evaluate the efficiency and feasibility of contrast-enhanced ultrasound (CEUS) with Sonovue in assessing of renal cell carcinomas (RCCs) following ultrasound (US)-guided percutaneous microwave ablation (MWA). "
|1.||Ethanol (Ethyl Alcohol)
|3.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|10.||SHU 508 (Levovist)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Quantum Dots (Quantum Dot)